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Metabolomics reveals 
impaired maturation of HDL 
particles in adolescents with 
hyperinsulinaemic androgen 
excess
Sara Samino1,3, Maria Vinaixa1,2,3, Marta Díaz1,5, Antoni Beltran1,3, Miguel A. Rodríguez1,3, 
Roger Mallol1,2, Mercedes Heras1,4, Anna Cabre1,4, Lorena Garcia3, Nuria Canela3, Francis de 
Zegher6, Xavier Correig1,2, Lourdes Ibáñez1,5 & Oscar Yanes1,2,3
Hyperinsulinaemic androgen excess (HIAE) in prepubertal and pubertal girls usually precedes 
a broader pathological phenotype in adulthood that is associated with anovulatory infertility, 
metabolic syndrome and type 2 diabetes. The metabolic derangements that determine these long-
term health risks remain to be clarified. Here we use NMR and MS-based metabolomics to show 
that serum levels of methionine sulfoxide in HIAE girls are an indicator of the degree of oxidation 
of methionine-148 residue in apolipoprotein-A1. Oxidation of apo-A1 in methionine-148, in turn, 
leads to an impaired maturation of high-density lipoproteins (HDL) that is reflected in a decline of 
large HDL particles. Notably, such metabolic alterations occur in the absence of impaired glucose 
tolerance, hyperglycemia and hypertriglyceridemia, and were partially restored after 18 months of 
treatment with a low-dose combination of pioglitazone, metformin and flutamide.
Hyperinsulinemic androgen excess (HIAE) is now recognized as the phenotypic core of a broader 
pathological entity traditionally known as polycystic ovary syndrome (PCOS)1–4, which affects 8–21% 
of women of reproductive age worldwide5–7. HIAE is a hallmark already present in both obese and 
non-obese adolescent girls8,9 and precedes a phenotype in adulthood characterized by anovulatory infer-
tility, metabolic syndrome, type 2 diabetes (T2D)10 and possibly cardiovascular disease (CVD)11,12. HIAE 
girls, therefore, provide an opportunity for discovering metabolic derangements that can bring a better 
understanding of these long-term health risks in their early stages. In turn, these findings might prompt 
early therapeutic interventions in adolescent girls, thereby decreasing subsequent metabolic complica-
tions related to HIAE4.
In this context, mass spectrometry (MS) and nuclear magnetic resonance (NMR)-based metabo-
lomics have the potential to discover metabolic alterations in clinical samples. Metabolomics enables 
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the characterization of metabolites, the chemical entities that are transformed during metabolism and 
provide a functional readout of cellular biochemistry13. Global metabolite profiling studies are revealing 
new discoveries linking cellular pathways to biological mechanism, shaping our understanding of cell 
biology, physiology and medicine14–16.
Here we develop a comparative MS and NMR metabolomic analysis using serum samples of HIAE 
girls, and age-, weight- and ethnicity-matched healthy controls. Our goal is to identify as yet undefined 
metabolic alterations in HIAE that may help to understand the development of metabolic syndrome and 
T2D in adulthood.
Our results revealed an imbalance between pro-oxidant and anti-oxidant events in HIAE, which leads 
to oxidation of apolipoprotein A1 and impaired maturation of HDL particles. Notably, these metabolic 
derangements precede essential contributory factors to the metabolic syndrome and T2D, including 
impaired glucose tolerance, hyperglycemia or hypertriglyceridemia. We also demonstrate that a low-dose 
combination of pioglitazone, flutamide and metformin (PioFluMet) during 18 months restores the levels 
of oxidative markers to similar levels found in healthy girls.
Results
Endocrine and metabolic alterations associated with HIAE girls. Endocrine and metabolic 
parameters were compared between a group of 12 young, non-obese HIAE girls and 14 age-, weight- 
and ethnicity-matched healthy controls. Table 1 shows mean values and the standard error of the mean 
CTR HIAE p-value
Age (yr) 17.2 ± 0.4 16.3 ± 0.4 0.15
BW SDS 0.3 ± 0.1 -0.2 ± 0.4 0.58
Wt (kg) 58.8 ± 1.8 58.2 ± 1.2 0.92
Ht (cm) 163.9 ± 1.3 160.0 ± 1.5 0.06
BMI (Kg/m2) 21.8 ± 0.6 22.8 ± 0.5 0.23
BMI SDS 0.2 ± 0.2 0.5 ± 0.2 0.16
WBC (cell/mm3) 7.3 ± 0.3 7.8 ± 0.5 0.26
Neutrophils (x1000/mm3) 4.1 ± 0.3 4.4 ± 0.5 0.63
Lymphocytes (x1000/mm3) 2.2 ± 0.1 2.5 ± 0.22 0.41
N/L (ratio) 1.9 ± 0.2 2.0 ± 0.4 0.51
AST (μ L/L) 16.6 ± 0.7 16.8 ± 1.6 0.59
ALT (μ L/L) 13.6 ± 1.0 13.2 ± 1.1 0.83
Glucose (mg/dL) 89.1 ± 1.5 85.4 ± 2.0 0.14
oGTT MSG (mmol/L/h) n.d. 6.7 ± 0.3 –
oGTT MSI (μ U/L/h) n.d. 45.9 ± 5.4 –
Insulin (μ U/mL) 3.5 ± 0.6 10.3 ± 1.6 0.01
G/I ratio 32.8 ± 3.6 11.2 ± 1.9 0.0004
Total Cholesterol 143.9 ± 5.9 145.9 ± 6.8 0.75
HDL-cholesterol 52.6 ± 2.3 51.9 ± 3.3 0.77
LDL-cholesterol 80.5 ± 5.4 78.7 ± 4.5 0.88
Triglycerides 53.4 ± 3.6 76.8 ± 16.5 0.57
Testosterone (ng/dL) 32 ± 2.4 64.2 ± 10.2 0.05
DHEAS (μ g/dL) 222.1 ± 27.8 280.8 ± 31.5 0.03
Leptin (ng/mL) 13.9 ± 2.3 20.9 ± 2.7 0.05
usCRP (mg/L) 0.7 ± 0.2 1.1 ± 0.2 0.14
SOD (U/mL) 6.1 ± 0.3 5.4 ± 0.2 0.03
Table 1.  Anthropometric and biochemical variables in patients and age- and BMI-matched controls. 
Data are represented as mean ± (SEM). P-values are calculated from a robust Yuen-Welch’s t-test. BW SDS: 
Birth weight standard deviation score, Wt: weight, Ht: height, BMI: body mass index, BMI SDS: body mass 
index standard deviation score, WBC: white blood cells, N/L: Neutrophils/Lymphocytes, AST: aspartate 
transaminase, ALT: alanine aminotransferase, oGTT: oral glucose tolerance test, MSG: mean serum glucose, 
MSI: mean serum insulin, G/I ratio: Glucose/insulin ratio, HDL-cholesterol: high density lipoprotein – 
cholesterol, LDL-cholesterol: low density lipoprotein – cholesterol, DHEAS: dehydroepiandrosterone sulfate, 
usCRP: ultrasensitive-C-reactive protein, SOD: superoxid dismutase, n.d.: not determined
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(SEM) for each variable. As expected by definition, endocrine alterations in adolescent HIAE girls rel-
ative to healthy controls included increased significant (p ≤ 0.05) serum levels of insulin, testosterone, 
dehydroepiandrosterone sulfate (DHEAS) and leptin. On the other hand, the fasting glucose to insulin 
ratio was decreased in HIAE girls. Levels of superoxide dismutase (SOD), a key antioxidant enzyme pro-
tecting the cells, were also decreased in HIAE girls. Triglycerides, LDL-cholesterol and HDL-cholesterol 
levels did not show differences between HIAE and healthy control girls.
Thus, hyperinsulinemia with normal fasting glucose levels in HIAE girls may reflect insulin resistance, 
as suggested by the increased ratio of glucose to insulin. However, we could observe no evidence of 
impaired glucose tolerance, hyperglycemia or hypertriglyceridemia at this early age.
Alteration of the VLDL, LDL and HDL serum profile in HIAE girls. Dyslipidemia is a risk factor 
linked to metabolic syndrome, T2D and CVD17. Here we studied the lipoprotein profile of HIAE girls 
beyond the standard measurement of cholesterol content of lipoproteins. By using an advanced lipopro-
tein analysis based on nuclear magnetic resonance (NMR) spectroscopy18, 1H-NMR allow to characterize 
the size and relative abundance of lipoprotein particles in serum. The use of NMR-derived lipoprotein 
subclasses improved cardiovascular risk stratification for subclinical atherosclerosis in comparison to 
conventional lipids19. Briefly, depending on the size of the lipoprotein particle, the methyl moieties of the 
lipids in lipoproteins resonate at slightly different frequencies, the smaller particles resonating at lower 
frequencies (Fig. 1a). Our NMR-derived lipoprotein subclasses were defined as VLDL, large LDL, small 
LDL, large HDL, medium HDL, and small HDL.
Relative levels of VLDL, small LDL and large LDL were significantly increased in HIAE relative 
to control girls. In contrast, the relative abundance of large, medium and small HDL subclasses was 
decreased in HIAE, with the greatest decline associated with large HDL (Fig. 1b). Supplementary Table 
1 shows the differences in serum lipoproteins between HIAE girls and healthy controls. The characteri-
zation of lipoprotein subclasses by NMR revealed a dyslipidemic profile in HIAE girls, which is similar 
to the one observed in the metabolic syndrome and its associated pathologies; T2D and CVD20.
Metabolomics reveals elevated levels of methionine sulfoxide and altered glutathione bio-
synthesis in HIAE girls. Our LC-qTOF MS and MS/MS-based untargeted metabolomic approach 
revealed lower levels of methionine in serum samples of HIAE girls, which were associated with greater 
levels of methionine sulfoxide (MetOx) in these patients, indicating increased oxidation of this amino 
acid (Supplementary Table 2). Furthermore, levels of γ -glutamyl dipeptides were increased in HIAE 
girls. γ -glutamyl dipeptides are involved in the γ -glutamyl cycle transporting amino acids into cells and 
synthesizing reduced glutathione (GSH), a key reducing agent that protects cells from oxidative damage. 
The NMR analysis, in addition, revealed lower levels of glycine in HIAE girls (Supplementary Table 3). 
Glycine can be added to the C-terminal of γ -glutamylcysteine (Glu-Cys) via the enzyme glutathione 
synthetase to produce GSH.
Figure 1. Lipoprotein profile measured by NMR spectroscopy. (A) Bipolar LED pulse sequence 1H NMR 
spectra of a HIAE serum showing the fitting of the methyl band using seven Lorentzian functions derived 
from our previously described methodology18. (B) The amount of lipoprotein particles is expressed as the 
percentage of particles for every lipoprotein subclass with regard to the total number of particles. Row-
wise normalized areas showed as mean± sem. VLDL: very low-density lipoprotein, lLDL: large low-density 
lipoprotein, sLDL: small low-density lipoprotein, lHDL: large high-density lipoprotein, mHDL: medium 
high-density lipoprotein, sHDL: small high-density lipoprotein
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Next, all these changes in metabolites were validated and complemented with additional metabolites 
by targeted analyses of the serum samples using triple-quadrupole mass spectrometry (QqQ MS) with 
multiple reaction monitoring (MRM) (when chemical standards were commercially available) (Table 2). 
We confirmed that a drop in methionine levels (Fig.  2A) is accompanied by an increase in MetOx 
(Fig. 2B) in HIAE girls. To discard that an artifactual conversion of methionine to MetOx during sample 
preparation and analysis21,22 could be the cause of the increased levels of MetOx in HIAE girls, we spiked 
the same amount of free deuterium labelled methionine (S-methyl-d3) in HIAE and control serum sam-
ples, followed by LC-QqQ MS detection. Supplementary Fig. 1 shows no significant differences in the 
levels of methionine-d3 or the artifactually-produced methionine-d3 sulfoxide (MetOx-d3), nor in the 
MetOx-d3/Met-d3 ratio, between HIAE and control samples. In both scenarios the percentage of arti-
factual MetOx-d3 represents less than 2% of the total methionine-d3 signal. Therefore, the minimal arti-
factual oxidation of methionine in our method does not impact on the relative and biological differences 
observed between HIAE and the control group.
The biosynthesis of glutathione (by quantifying reduced glutathione), the redox status (by quantifying 
the ratio of reduced to oxidized glutathione) and intermediates of the γ -glutamyl cycle were also elevated 
in HIAE girls (Fig. 3). These data demonstrate a redox dysregulation in HIAE girls.
As a result of the redox dysregulation, methionine residues in proteins can be oxidized by reactive 
oxygen species to MetOx23. Oxidation of methionine residues in apolipoprotein-A1 (apo-A1) has been 
associated with impaired reverse cholesterol transport by HDL, and consequently, impaired maturation 
of HDL particles24. This could partly explain the lower percentage of HDL particles, and more specifi-
cally, of large HDL particles in girls with HIAE (Fig. 1B). Since apo-A1 is the major protein component 
of HDL and one of the most abundant proteins in human serum25, we hypothesized that increased levels 
of free MetOx in HIAE serum may reflect greater oxidation of methionine residues in apo-A1.
Quantitative analysis of the MetOx-148/Met-148 ratio in apo-A1 by MALDI-TOF MS. To test 
the hypothesis that HIAE girls suffer from increased oxidation of methionine residues in apo-A1, we 
measured the ratio of MetOx/Met in apo-A1 using SDS-PAGE and MALDI-TOF MS (see the Methods 
section for details). In particular, we focused on a single methionine residue of apo-A1, Met-148, the 
oxidation of which has been associated with loss of lecithin cholesterol acyltransferase (LCAT) activity, 
a critical early step in reverse cholesterol transport26.
Apo-A1 sequence coverage was 61% on average and MetOx-148/Met-148 was calculated from the 
ratio of peak intensity of peptides m/z 1411.67 and m/z 1047.51 (sequence K.LSPLGEEMR.D). The ratio 
MetOx-148/Met-148 of apo-A1 was measured separately for each sample to minimize the spot-to-spot 
variability in MALDI MS. It is possible that the level of artifactual oxidation of Met-148 in this peptide 
could be greater than that of free methionine described above. However, based on Suppl. Fig. 1, we 
consider that the amount of artifactually-produced MetOx-148 from HIAE and control serum samples 
is similar, and consequently, it does not impact on the relative differences between groups.
The ratio MetOx-148/Met-148 in apo-A1 was significantly increased in HIAE girls compared with 
healthy controls (Fig.  4A). Furthermore, we found a positive and significant correlation (p = 6.95E-05 
and r = 0.8) between the ratio MetOx-148/Met-148 in apo-A1 and free methionine sulfoxide in serum 
(Fig. 4B). Levels of methionine sulfoxide in serum, therefore, correlate with the degree of oxidation of the 
Met-148 residue in apo-A1, which may reflect turnover and proteolytic degradation of apo-A1 proteins. 
% variation p-value
Methionine > − 100 0.00005
Methionine Sulfoxide 40 0.0018
5-oxoproline 39 0.005
Taurine 28 0.015
Glu-Cys 37 0.0002
Glu-Glu 35 0.027
Glutamate 33 0.004
GSH 34 0.036
GSH/GSSG 29 0.023
Glu-Taurine* >100 0.0000003
Glu-Gly* 71 0.00015
Table 2.  Targeted metabolomics. Percentage of variation and p-values (Yuen-Welch’s t-test) of metabolites. 
Negative and positive values indicate lower and higher levels, respectively, in girls with HIAE relative to 
healthy controls. Glu: glutamate, Cys: cysteine, GSH: glutathione, Gly: glycine, GSH/GSSG: glutathione/
glutathione disulfide. *Glu-taurine and *Glu-Gly could not be quantified by LC-QqQ in MRM mode due to 
the lack of pure standards and reported values are from LC-qTOF MS.
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Figure 2. Targeted LC-QqQ MS analysis of methionine and methionine sulfoxide. The scatter plots show 
the abundance of methionine (A) and methionine sulfoxide (B) in controls and HIAE serum samples and 
trimmed mean (P < 0.05) (controls are depicted in red and HIAE in blue).
Figure 3. Identified and quantified metabolites involved in the γ-glutamyl cycle. The scatter plots show 
the abundance of individual metabolites in control and HIAE serum samples and trimmed mean (P < 0.05) 
(control in red and HIAE in blue). Glycine was measured by 1H-NMR and the other metabolites by LC-
QqQ MS.
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Finally, we found a negative correlation (p = 1.13E-03 and r = − 0.7) between the number of large (i.e., 
mature) HDL particles and methionine sulfoxide in serum (Fig.  4C), which reinforces our hypothesis 
that levels of methionine sulfoxide in serum reflect HDL oxidation, and indirectly, impaired maturation 
of HDL particles.
Metabolic changes after 18 months of PioFluMet polytherapy in HIAE girls. Ibáñez and col-
leagues demonstrated that a low-dose combination of pioglitazone, flutamide and metformin (PioFluMet) 
proved to be more beneficial than oral contraceptives in regulating endocrine-metabolic parameters, 
decreasing inflammation and visceral and hepatic fat, and in improving markers of cardiovascular 
health27.
Here, the PioFluMet polytherapy resulted in a reduction in insulin concentrations (Supplementary 
Fig. 2). We also measured if the novel metabolic markers described above in HIAE girls are subject 
to regulation by the PioFluMet polytherapy. Metabolites involved in the biosynthesis of GSH via the 
γ -glutamyl cycle, the size and relative abundance of lipoprotein particles, and the degree of oxidation of 
Apo-A1 through the MetOx-148/Met-148 ratio were monitored using NMR and MS in the serum of 6 
patients after 18 months of PioFluMet treatment.
The abundance of individual markers was scaled to unit variance and projected using an unsupervised 
principal component analysis (PCA) (Fig. 5A). The scores plot reveals two clusters along PC1 (~47% of 
the variance) corresponding to HIAE girls on the one hand, and healthy controls and HIAE girls treated 
with PioFluMet on the other. This distribution indicates that the metabolic state of HIAE girls after 18 
months of PioFluMet treatment more closely resembles the state of healthy girls, suggesting an overall 
improvement of the metabolic derangements in these girls. To interpret the pattern displayed in the 
scores plot, Fig.  5B shows a loading bar plot of the PCA using each individual metabolic marker. The 
relative abundance of large HDL particles and levels of free methionine in serum are the two largest 
contributing variables to positive values in PC1. After the treatment with PioFluMet, the levels of methio-
nine and large HDL particles recovered to similar levels found in healthy girls (Fig. 5C,D). Likewise, the 
levels of methionine sulfoxide and the oxidation of Apo-A1 in the Met-148 residue decreased after the 
treatment, reaching similar or even lower levels than those seen in healthy girls (Fig. 5E,F).
Discussion
A better understanding of hyperinsulinemic androgen excess (HIAE) in non-obese adolescents may 
help to identify early causes of pre-diabetic states28 and possibly cardiovascular events29 in adulthood. 
Ultimately, novel insights should sharpen the perspective of early HIAE prevention4.
Our study indicates an imbalance between pro-oxidant and anti-oxidant mechanisms in HIAE girls. 
The pro-oxidant events include increased oxidation of methionine residues in apo-A1 and accumulation 
of the oxidative marker methionine sulfoxide in HIAE serum. Interestingly, these patients appear to have 
the capacity to activate a compensatory anti-oxidant mechanism that probably aims at regulating their 
redox status by synthesizing glutathione (GSH) through the γ -glutamyl cycle30. Redox imbalances have 
been also described in adult women with a PCOS phenotype31–33, atherosclerotic diseases34, diabetes35,36 
and metabolic syndrome37. However, the underlying causes of these associations remain unclear.
High-density lipoprotein (HDL) has protective activities against atherosclerosis, including its role in 
reverse cholesterol transport38,39. Its antioxidant and anti-inflammatory functions40 are generally associ-
ated with lower risk of cardiovascular disease41, metabolic syndrome and T2D42–44. The functional status 
of HDL is closely linked to its primary protein component, apo-A1. Oxidation of methionine residues 
Figure 4. Oxidation of Apo-A1 and correlation of measurements. (A) Ratio of MetOx-148/Met-148 
in apo-A1 (P < 0.05) measured by MALDI-TOF MS from the intensity of peptide K.LSPLGEEMR.D. (B) 
Statistically significant positive correlation (P = 6.95E-05 and r = 0.8) between free methionine sulfoxide in 
serum, as measured by LC-QqQ MS, and the oxidation state of apo-A1. (C) Statistically significant negative 
correlation (P = 1.13E-03 and r = − 0.7) between free levels of methionine sulfoxide in serum and the 
percentage of large HDL particles, as measured by NMR. Controls are depicted in red and HIAE in blue.
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in apo-A1 has been shown to impair reverse cholesterol transport by HDL24. Specifically, the oxidation 
of Met-148 in apo-A1 impairs apo-A1’s ability to activate LCAT24. LCAT is the enzyme responsible for 
converting free cholesterol into cholesteryl ester, which is then sequestered into the core of a lipoprotein 
particle, transforming newly synthesized HDL into spherical HDL. In our study, the increased oxidation 
of Met-148 residues in apo-A1 and the lower percentage of large (i.e., mature) HDL particles observed 
in HIAE girls, suggest impaired HDL function.
Similarly, recent experimental studies point out that the concentration of HDL particles, rather than 
the cholesterol carried by these particles, might be the appropriate parameter for assessing the function 
of HDL45. The HDL-cholesterol levels in HIAE girls within normal limits and the lower concentration 
of HDL particles in these girls, as measured by routine enzymatic colorimetric methods and NMR, 
respectively, might suggest higher levels of cholesterol-overloaded HDL particles46, with potentially less 
capacity for cholesterol efflux. Further work is needed to explore the link between oxidation of methio-
nine residues in apo-A1, cholesterol-overloaded HDL particles and impaired HDL functions.
Figure 5. Metabolic changes after 18 months of PioFluMet polytherapy. (A) PC1/PC2 scatter scores 
plot and (B) PC1 loading bar plot of PCA showing all the metabolites measured in HIAE girls after the 
treatment. (C) Relative intensity of free methionine in serum as measured by LC-QqQ MS. (D) Percentage 
of large HDL particles in serum as measured by NMR. (E) Relative intensity of free methionine sulfoxide 
in serum as measured by LC-QqQ MS. (F) Ratio of MetOx-148/Met-148 in apo-A1 calculated from the 
intensity of the pepide K.LSPLGEEMR.D as measured by MALDI-TOF MS.
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Recently, Lee et al. demonstrated that low sugar consumption is associated with increasing HDL levels 
in females during adolescence47. In addition, excessive sugar intake in combination with hyperandrogen-
ism causes oxidative stress48–50. In this context, we postulate that the current period of caloric abundance 
and chronically positive energy balance for most adolescents51, induces oxidation of lipoprotein particles 
and impaired lipoprotein function. Our data and those of others52,53, indicate that alterations in lipopro-
tein metabolism precede impaired fasting glycemia, impaired glucose tolerance and hypertriglyceridemia 
(Fig.  6). This suggests that the triad of methionine sulfoxide in serum, size of HDL particles and the 
ratio of methionine oxidation in apo-A1 may potentially become a novel biomarker of pre-diabetes and 
metabolic syndrome. Further work is needed to study this combination of biomarkers in the general 
population.
Finally, early treatment with a low-dose combination of PioFluMet proves again its efficacy in revert-
ing androgen excess and hyperinsulinemia54, while improving the lipoprotein profile and levels of oxida-
tive stress markers in HIAE girls. These observations extend further the benefits of therapies leading to 
a more physiological condition in HIAE girls, questioning the rationale for applying symptom-directed 
therapies that might potentially impact on later co-morbidities55.
Methods
The methods were carried out in accordance with the approved guidelines of ISRCTN, which is a pri-
mary clinical trial registry recognised by WHO and ICMJE. The study was registered in Feb 2010 as 
ISRCTN45546616 (http://www.isrctn.com/ISRCTN45546616).
Study population. The study population consisted of 12 non-obese adolescents (age, 16.3 ± 0.4 yr; 
BMI, 22.8 ± 0.5 Kg/m2) diagnosed with HIAE and 14 age-, weight- and ethnicity-matched healthy con-
trols. HIAE girls were recruited at the Endocrinology Unit of the Sant Joan de Déu Children’s Hospital, 
Barcelona (Spain), among those randomized into a clinical study comparing the effects of a low-dose 
combination of Pioglitazone (7.5 mg/d) + Flutamide (62.5 mg/d) + Metformin (850 mg/d) (PioFluMet) 
with those of a frequently prescribed oral contraceptive [cyproteroneacetate 2 mg + 35 mcg ethynilestra-
diol for 21 of 28 d, and placebo for 7 of 28 d]54. The girls were chosen among those having enough serum 
sample left to allow for the required assessments. Controls were recruited among age-matched student 
mates with no clinical signs of androgen excess and regular menstrual cycles.
Inclusion criteria were: 1) hyperinsulinemia, defined as fasting-insulinemia above 150U/ml and/or 
hyperinsulinemia on a standard 2-h oral glucose tolerance test, defined as peak insulin levels >150 U/mL 
and/or mean serum insulin > 84 μ U/mL; and 2) the presence of both clinical and biochemical androgen 
excess, as defined by the following: hirsutism score above 8 (Ferriman-Gallwey), amenorrhea (no menses 
for 3 months) or oligomenorrhea (menstrual cycles longer than 45 d); and increased levels of circulating 
androstenedione and/or testosterone in the follicular phase of the cycle (d 3–7) or after 2 months of 
amenorrhea54.
Exclusion criteria were: evidence of anemia, thyroid dysfunction, bleeding disorder, Cushing syn-
drome, or hyperprolactinemia; glucose intolerance; diabetes mellitus; late-onset adrenal hyperplasia; 
abnormal electrolytes; abnormal screening of liver or kidney functions; use of medication affecting 
gonadal or adrenal function, or carbohydrate or lipid metabolism. Pregnancy risk was a particular 
Figure 6. Proposed mechanism to explain the long-term health risks of hyperinsulinaemic androgen 
excess. Schematic representation of the underlying pathway by which HIAE is associated with long-term 
health risks, namely metabolic syndrome, diabetes and cardiovascular disease.
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exclusion criterion that was not only taken into account at study start, but was also maintained through-
out the study in the PioFluMet subgroup.
Ethics. This clinical study was registered as ISRCTN12871246 and conducted in Sant Joan de Déu 
University Hospital (Barcelona, Spain), after approval by the Institutional Review Board of Sant Joan de 
Déu University Hospital, and after written informed consent by the parents and assent by each partici-
pating girl.
Global metabolomics profiling. Untargeted metabolomic analyses on serum samples of HIAE and 
control girls were performed using two analytical platforms: 1H-NMR and LC-ESI-QTOF. Each serum 
sample was split into two aliquots and run in parallel using the two analytical platforms. For the NMR 
measurement 250 μ L of serum were mixed with 250 μ L of phosphate buffer (0.75 mM Na2HPO4 adjusted 
at pH 7.4, and 20% D2O to provide the field frequency lock). The final solution was transferred to a 5 mm 
NMR tube and kept refrigerated at 4 °C in the autosampler until the analysis. 1H-NMR spectra were 
recorded at 310 K on a Bruker Avance III 600 spectrometer operating at a proton frequency of 600.20 MHz 
using a 5 mm CPTCI triple resonance (1H, 13C, 31P). Two different 1H-NMR pulse experiments were per-
formed for each sample: 1) Nuclear Overhauser Effect Spectroscopy (NOESY)-presaturation sequence 
to suppress the residual water peak; and 2) Carr-Purcell-Meiboom-Gill sequence (CPMG, spin-spin T2 
relaxation filter) with a total time filter of 410 ms to attenuate the signals of serum macro-molecules to 
a residual level.
The second aliquot was used for LC-MS analysis. 30 μ L of serum sample was mixed with 120 μ L of 
cold ACN/H2O (1:1) with 1% meta-phosphoric acid (MPA) and 0.1% formic acid (previously filtered), a 
simple and rapid extraction method particularly indicated for minimizing oxidation of redox species56,57. 
Samples were vortexed vigorously for 30 seconds and stored at –20 °C for 2 hours to enable protein pre-
cipitation. Subsequently, samples were centrifuged 15 minutes at 4 °C and 22600 RCF and the superna-
tant was transferred to a LC-MS vial. Samples were injected in a UHPLC system (1290 Agilent) coupled 
to a quadrupole time of flight (QTOF) mass spectrometer (6550 Agilent Technologies) operated in pos-
itive electrospray ionization (ESI+ ) mode. Metabolites were separated using either C18-RP (ACQUITY 
UPLC HSS T3 1.8 μ m, Waters) or HILIC (ACQUITY UPLC BEH 1.7 μ m, Waters) chromatography at 
a flow rate of 0.4 mL/min. The solvent system in C18-RP was A = 0.1% formic in water, and B = 0.1% 
formic in acetonitrile. The linear gradient elution started at 100% A (time 0–3 min) and finished at 100% 
B (20–21 min). The solvent system in HILIC was A = 50mM NH4OAc in water, and B= ACN. The linear 
gradient elution started at 95% B (time 0–2 min) and finished at 55% B (6 min). The injection volume 
was 2 μ L. ESI conditions were gas temperature, 225 °C; drying gas, 13 L min–1; nebulizer, 20 psig; frag-
mentor, 125 V; and skimmer, 65 V. The instrument was set to acquire over the m/z range 80–1200 with 
an acquisition rate of 4 spectra/s. Quality control samples (QC) consisting of pooled serum samples of 
all patients were used. QC samples were injected before the first study sample and then periodically after 
five-study samples. Furthermore, real samples were randomized to reduce systematic error associated 
with instrumental drift. MS/MS was performed in targeted mode, and the instrument was set to acquire 
over the m/z range 50–1000, with a default iso width (the width half-maximum of the quadrupole mass 
bandpass used during MS/MS precursor isolation) of 4 m/z. The collision energy was fixed at 20 V. With 
the exception of glutamyl taurine and glutamyl glycine, all metabolites were identified conforming to 
Level 1 as specified by the Metabolomics Standards Initiative58, that is, by comparison with accurate 
mass, retention time and MS/MS data of chemical standards analysed in our laboratory with the same 
analytical platform and method. Glutamyl taurine and glutamyl glycine conform Level 2 (i.e., putatively 
annotated compound) since we did not find the chemical standards. Still, their experimental MS/MS 
spectra coincide with the expected fragmentation pattern of these dipeptides. Metabolomic data has been 
deposited in the MetaboLights database (accession code: MTBLS103).
Targeted metabolomics. Relevant metabolites were measured again using an UHPLC system (1290 
Agilent) coupled to a triple quadrupole (QqQ) MS (6490 Agilent Technologies) operated in multi-
ple reaction monitoring (MRM) and positive electrospray ionization (ESI+ ) mode. MRM transitions 
were: methionine (150→ 56, 61), methionine sulfoxide (166→ 56, 74), taurine (126→ 41, 85), gluta-
mate (148→ 56, 84), cysteine-glycine (179→ 59, 116), glutathione (308→ 76, 162), glutathione disulfide 
(613→ 355, 484), glutamate-glutamate (277→ 84, 130), glutamate-cysteine (251→ 84, 122), 5-oxoproline 
(130→ 56, 84).
Spiking experiments with stable isotope labelled methionine. Free deuterium labeled methio-
nine (S-methyl-d3) was spiked into HIAE and control serum samples at a final concentration 0,5 mM. 
Following metabolite extraction with meta-phosphoric acid (see details above), methionine-d3 and 
MetOx-d3 were measured using a LC-QqQ MS (6490 Agilent Technologies) in ESI+ and MRM mode. 
MRM transitions were: methionine-d3 (153→ 56, 64, 107), methionine-d3 sulfoxide (169→ 74, 56, 78).
Characterization of lipoprotein classes. 1H NMR spectra were recorded at 310 K on a Bruker 
Avance III 600 spectrometer operating at a proton frequency of 600.20 MHz (14.1 T). We used the 
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double stimulated echo (DSTE) pulse program with bipolar gradient pulses of 1 ms and a gradient pulse 
strength of 95% of the maximum strength of 53.5 Gauss cm−1 in order to completely attenuate signals 
from low molecular weight metabolites. The relaxation delay was 2 s, the free induction decays (FIDs) 
were collected into 64 K complex data points and 32 scans were acquired on each sample. The methyl 
signal was line-shape fitted using eight 1D Lorentzian functions using a modification of a previously 
reported protocol18. According to the NMR-derived lipoprotein sizes previously described, functions 2 
to 8 were associated with 1 VLDL, 2 LDL, and 4 HDL lipoprotein subclasses, respectively. For simplifi-
cation, functions 7 to 8 were grouped to obtain the small HDL subclass.
Data analysis and statistical methods. The acquired CPMG NMR spectra were phased, baseline 
corrected and referenced to the chemical shift of the α -glucose anomeric proton doublet at 5.23 ppm. 
Pure compound references in Bioref AMIX (Bruker), HMDB and Chenomx databases were used for 
metabolite identification. After baseline correction, intensities of each 1H-NMR regions identified in the 
CPMG 1D-NMR spectra were integrated for each sample entering the study using the AMIX 3.8 software 
package (Bruker, GmBH).
LC-MS (RP-C18 and HILIC ESI+ mode) data were processed using the XCMS software59 (version 
1.38.0) to detect and align features. A feature is defined as a molecular entity with a unique m/z and a 
specific retention time. XCMS analysis of these data provided a matrix containing the retention time, 
m/z value, and integrated peak area of greater than 38.000 features after the analytical variability had 
been corrected60. Only the integrated areas of those metabolite features above 5,000 spectral counts in 
at least one of the two groups were considered for quantification. The tab-separated text files containing 
LC-MS data were imported into Rstudio (version 3.0.2) where QC samples were used to filter analytical 
variation as previously described60. Univariate statistical analysis was performed using robust statistics 
(Yuen-Welch’s t-test). Differentially regulated metabolites (fold > 1.5) that passed our statistical criteria 
(p-value < 0.01) were characterized by LC-qTOF MS/MS and identified using the Metlin database and 
pure standards purchased on our lab. Regression models and multivariate data analysis were performed 
using Rstudio software version 3.0.2.
SDS-PAGE and trypsin digestion of apolipoprotein A1. Protein precipitation was carried out add-
ing 10% of pure trichloroacetic acid (TCA) to 10 μ L of serum. Samples were vortexed and incubated on 
ice for 1 hour. Samples were then centrifuged at 4 °C and 14.000 rpm for 15 minutes and the supernatants 
were discarded. 800 μ L of cold acetone (− 20 °C) were added to the pellet and proteins were suspended 
and incubated overnight (− 20 °C). Samples were centrifuged and the supernatant discarded again. This 
step was repeated and the pellet was air-dried. Pellet was resuspended with 100 μ L of urea (7M), thiourea 
(2M) and CHAPS (4%) buffer. 10 μ L of this solution were added to 30 μ L of Laemmli Buffer (4x). 40 μ L 
of such solution was applied to a home-made 12% acrylamide/bis-acrylamide SDS-PAGE gel.
Proteins were Coomassie stained. The band of interest corresponding to Apo-A1 (MW: 28,1 kDa) was 
manually excised from 1D SDS-PAGE gels, destained and washed with 25 mM ammonium bicarbonate 
(AmBic) for 15 min followed by a wash with acetonitrile for 15 min. These washes were twice repeated 
and samples were finally dehydrated with 100% acetonitrile and dried in a Speed-Vack concentrator. 
Apo-A1 was cysteine carbamidomethylated by placing the dried gel at 56 °C for 1 h in a reducing solution 
containing 10 mM DTT and 50 mM AmBic. Alkylation of the cysteines was achieved by incubation of the 
gel for 30 min in the dark with 55 mM iodoacetamide in 25 mM AmBic buffer. Gel pieces were alternately 
washed with 25 mM AmBic and 25 mM AmBic with acetonitrile, and finally dehydrated with 100% ace-
tonitrile and dried under vacuum. Gel pieces were incubated with 12.5 ng/μ l sequencing grade trypsin 
(Roche Molecular Biochemicals) in 25 mM AmBic overnight at 37 °C. After digestion, the supernatants 
were separated. Peptides were extracted from the gel pieces into 50% ACN, 0.1% trifluoroacetic acid. 
For each extraction, samples were incubated for 10 min in an orbital shaker. All extracts were pooled 
and the volume reduced using a vacuum concentrator. In order to obtain a suitable sample for mass 
spectrometry analysis the pellet was resuspended in 25 μ L of 0.1% TFA/water, desalted and concentrated 
using C18 ZipTips (Millipore). Tryptic peptides were sequentially eluted with 5 μ L of 70% acetonitrile 
with 0.1% TFA in water.
MALDI-TOF MS analysis of Apo-A1. Samples were spotted on the MALDI plate following the 
dried-droplet method. Briefly, 1 μ l of the reconstituted in-gel digest sample was spotted on a BigAnchorChip 
target plate (Bruker Daltonics), followed by 1 μ l of matrix (10 mg/ml α -cyano-4-hydroxycinnamic acid 
matrix (Bruker Daltonics) in 50% ACN, 0.1% TFA). Sample and matrix mixture was dried at room 
temperature. Mass spectra were obtained on an UltrafleXtreme (Bruker Daltonics, Bremen, Germany) 
matrix-assisted laser desorption ionization–tandem time of flight (MALDI-TOF/TOF) mass spectrom-
eter. Mass spectra were recorded in positive ionizat ion ref lec tron mode in  the  mass  range 
of  700–3500 Da.  Operat ing condit ions  were  as  fol lows: ion source 1 = 25.00 kV, ion source 
2 = 24.40 kV, lens voltage = 8.50 kV, reflector voltage = 26.45 kV, optimized pulsed ion extraction 
time = 130 ns, matrix suppression = 500 Da. 1500 single-shot spectra were accumulated by recording 
50-shot spectra at 10 random positions using fixed laser attenuation. Mass spectra were externally cali-
brated using a standard peptide mixture (Bruker); calibration was considered good when a value below 
1 ppm was obtained.
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Peptide mass fingerprinting of Apo-A1 and quantization of the ratio MetOx-148/Met-
148. ProteinScape software (Bruker) supported by the Mascot search engine (Matrix Science) was 
used with the following parameters: SWISS-PROT non-redundant database filtered by Homo sapiens 
taxonomy, two missed cleavage permission, 50-ppm measurement tolerance.
Carbamidomethylation of cysteines was set as a fixed modification and methionine oxidation was set 
as a variable modification. Positive identifications were accepted with a Mascot score higher than that 
corresponding to a P value of 0.05. The quantification of the ratio MetOx-148/Met-148 was performed 
using the intensity of the peptide K.LSPLGEEMS.D (Flex Analysis, Bruker).
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